{"id":"heliox21","safety":{"commonSideEffects":[{"rate":"rare","effect":"Respiratory acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Heliox21 works by decreasing the density of the airway gas, making it easier for patients to breathe. This can be particularly beneficial for patients with conditions such as status asthmaticus or severe chronic obstructive pulmonary disease (COPD).","oneSentence":"Heliox21 is a mixture of helium and oxygen used to reduce the work of breathing in patients with respiratory distress.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:46.438Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of respiratory distress in patients with status asthmaticus or severe COPD"}]},"trialDetails":[{"nctId":"NCT03171142","phase":"PHASE3","title":"Effect of Heliox on RSV Bronchiolitis","status":"COMPLETED","sponsor":"Wael Seliem","startDate":"2015-05-01","conditions":"RSV Infection, Acute Bronchiolitis","enrollment":104},{"nctId":"NCT01498432","phase":"PHASE4","title":"Physiological Response to Heliox21 and Air O2","status":"UNKNOWN","sponsor":"University College, London","startDate":"2012-01","conditions":"Respiratory Insufficiency","enrollment":38},{"nctId":"NCT01383850","phase":"PHASE2","title":"NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS)","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2008-02","conditions":"Respiratory Distress Syndrome, Bronchopulmonary Dysplasia","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heliox21","genericName":"Heliox21","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heliox21 is a mixture of helium and oxygen used to reduce the work of breathing in patients with respiratory distress. Used for Treatment of respiratory distress in patients with status asthmaticus or severe COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}